Alectinib Superior to Crizotinib for ALK+ NSCLC.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2017-090
Abstract: Findings from the global phase III ALEX trial unequivocally show that alectinib is superior to crizotinib as first-line therapy for ALK+ non-small cell lung cancer. Alectinib more than doubled progression-free survival, significantly reduced the incidence… read more here.
Keywords: crizotinib alk; alk nsclc; alectinib superior; superior crizotinib ... See more keywords
Durvalumab May Be Effective in Patients with EGFR+/ALK+ NSCLC.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2018-049
Abstract: PD-L1 blockade with durvalumab achieves responses in patients with EGFR+/ALK+ and EGFR-/ALK- NSCLC. read more here.
Keywords: egfr alk; durvalumab may; alk nsclc; may effective ... See more keywords
Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.9065
Abstract: 9065Background: BRG is a potent and selective ALK inhibitor with preclinical and clinical activity against wild-type ALK and a broad range of mutants associated with clinical CRZ resistance, including G1202R. Herein we examine the association… read more here.
Keywords: brg; resistant alk; alk; alk nsclc ... See more keywords
Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.9022
Abstract: 9022Background: The primary analysis of the J-ALEX (JapicCTI-132316) study for the ALK-inhibitor naive ALK+ NSCLC demonstrated superior progression-free survival (PFS) in Japanese patients randomiz... read more here.
Keywords: alk nsclc; alk; alk inhibitor; study ... See more keywords
Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach
Sign Up to like & getrecommendations! Published in 2021 at "Oncotarget"
DOI: 10.18632/oncotarget.27875
Abstract: Around 3–7% of patients with non-small cell lung cancer (NSCLC), which represent 85% of diagnosed lung cancers, have a rearrangement in the ALK gene that produces an abnormal activity of the ALK protein cell signaling… read more here.
Keywords: head; alk; first line; alk nsclc ... See more keywords